Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
about
Dietary and nutritional considerations for inflammatory bowel diseaseOral 5-aminosalicylic acid for induction of remission in ulcerative colitisProbiotics for maintenance of remission in ulcerative colitisProbiotics for maintenance of remission in ulcerative colitisProbiotics for maintenance of remission in Crohn's diseaseProbiotics for the maintenance of remission in Crohn's diseaseBacteriotherapy: the time has comeToward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917Probiotics in the management of ulcerative colitisSynbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trialMaintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazineRole and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An updateDiet therapy for inflammatory bowel diseases: The established and the newClinical Uses of ProbioticsBacteriocins as Potential Anticancer AgentsTh17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel DiseasesDevelopment of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agentProbiotics in inflammatory bowel diseases and associated conditionsIntestinal permeability--a new target for disease prevention and therapyInsights from 100 Years of Research with Probiotic E. ColiNew insights into therapeutic strategies for gut microbiota modulation in inflammatory diseasesGut bacteria in health and diseaseSystematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel diseaseShould yoghurt cultures be considered probiotic?Identification and characterisation of an iron-responsive candidate probioticMechanisms of Natural Tolerance in the IntestineImmune therapy in inflammatory bowel disease and models of colitis.A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel diseaseProbiotics under the regulatory microscope.Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease.Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease.Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli.Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study.Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrityPost-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.A study of fructo oligosaccharides in the prevention of travellers' diarrhoea.Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)Potential role of nutraceutical compounds in inflammatory bowel disease
P2860
Q22251396-951D6843-D365-4497-ABEF-8242C06CCAA7Q24198024-CC02A557-14F9-42B8-9F37-38C67DCDF7E9Q24234400-34C2F4D1-D9A3-4B4B-BC09-239E50432B94Q24242289-5D7BAC81-2E23-42FA-884E-CDA68D66175AQ24244110-F90274B1-D9DE-40D5-B023-95F3CD75B220Q24246901-DADCFBE5-E938-40C6-B9E2-0ED5CE40377BQ24525256-20E6F4D7-20DA-40DC-A912-23B78C419D3EQ24535758-5CCAAE18-04B7-48AF-915C-8541AD854C7AQ24561803-8BA692A1-FB2F-4774-8FD8-0F7879DAE3D9Q24630676-23AC15BB-07DC-4CC8-AE85-19F85FE99E35Q24685494-90536B9A-F518-4B8B-B3BA-FC905F9C6F97Q24685766-61AAC893-D570-4561-8BF2-3AB30DF288E2Q26746916-2D845852-C64C-4095-AE45-B891A75274B3Q26768564-84185627-A5F2-4E12-916D-907951C84764Q26769032-294958A8-A077-4FA4-BA47-F881F09CE6B1Q26776177-49670993-3D7B-47D6-B5D6-757F57504492Q26784194-8AD3E43A-8736-44D8-974A-199C958EE57AQ26991504-EC9A039C-3355-4FBE-8596-0C80B2862D07Q27002496-79192908-2901-4B1D-BB52-7692E35D394EQ27015884-1D528096-6EBB-4403-A4E3-806797AA3C9CQ28079219-BE2B8B3C-DDA5-43B5-82DE-BD4C8EE66A1DQ28079638-4A546706-FB16-4073-91FB-F8FBCEDBB60CQ28238138-45B43C0E-0969-4852-9731-D67848431BBCQ28254207-E3104FAD-EE9A-4345-A67D-A1864F2F96B9Q28262022-61BB5FDB-9D88-4C31-AAC1-7F3FBF60F6E5Q28743610-6CE5FD6F-3D12-42F5-B8BA-64C75F325119Q29031968-A210CB73-0FED-48F9-BE6B-0166A37DE9F8Q30774968-574DD416-26A1-485F-84BD-E79526A7EF5DQ30861977-A1C1D6AC-8E3B-4DDA-9CEC-C16E23175B98Q33201542-197C63DC-C325-4463-B482-1EE79F2F23D5Q33226168-D1635755-265F-42B1-815F-60104586CE7EQ33244259-B1FEE68E-B518-42AB-A616-6D3CE77092F7Q33256876-D3A51C5C-D2A8-4F05-991E-D28CC16C0CD1Q33280033-5D3A4279-A76D-4ED8-ABE7-89CB182E0FDDQ33296911-B6D3324F-0500-4192-A473-11FB3F2A0B05Q33309955-3FA67CF2-73B9-43EB-8D7A-9706B31EFBE6Q33406281-971911FA-4FAD-41FE-8547-9089B4C570C2Q33423514-D14329F4-8DAC-4BB9-81CF-16A21A0C586DQ33557634-63D3F06D-B098-46BE-AB64-7BA4F87CA510Q33572633-66491601-F86E-4C1D-8587-03D22F195D14
P2860
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@ast
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@en
type
label
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@ast
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@en
prefLabel
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@ast
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@en
P2093
P1433
P1476
Non-pathogenic Escherichia col ...... e colitis: a randomised trial.
@en
P2093
A M Snelling
B J Rembacken
D M Chalmers
P M Hawkey
P304
P356
10.1016/S0140-6736(98)06343-0
P407
P577
1999-08-01T00:00:00Z